SCHEMBL13638456

SCHEMBL13638456

C=C1CC(Nc2nccc(-c3ccc(CCCCOC)s3)n2)CC(C)(C)N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 5/20 0.42
CHUK O15111 5/20 0.42
IKBKG Q9Y6K9 5/20 0.42
CDK4 P11802 5/20 0.35
CDK1 P06493 4/20 0.35
CCNA2 P20248 4/20 0.35
CDK2 P24941 4/20 0.35
CCNE1 P24864 2/20 0.35
CCND3 P30281 2/20 0.35
CDK6 Q00534 2/20 0.35
MAPK1 P28482 2/20 0.33
CCNB1 P14635 2/20 0.32
CCND1 P24385 2/20 0.32
CCNA1 P78396 2/20 0.32
MAP3K14 Q99558 3/20 0.31
AKT3 Q9Y243 3/20 0.31
GSK3B P49841 1/20 0.30
EIF2AK2 P19525 1/20 0.30
IGF1R P08069 1/20 0.30
FGFR1 P11362 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13638303 0.89 IKBKB (0.43) IKBKBCHUKIKBKGCDK4CDK1
SCHEMBL13638292 0.89 KDR (0.37) IKBKBCHUKIKBKGCDK4CDK1
SCHEMBL13638306 0.89 IKBKB (0.34) IKBKBCHUKIKBKGCDK4CDK1
SCHEMBL13638429 0.88 IKBKB (0.34) IKBKBCHUKIKBKGCDK4CDK1
SCHEMBL13633566 0.88 IKBKB (0.45) IKBKBCHUKIKBKGCDK4CDK1
Hydrochloric Acid SCHEMBL3471377 0.87 IKBKB (0.44) IKBKBCHUKIKBKGCDK4CDK1
SCHEMBL13638432 0.87 IKBKB (0.39) IKBKBCHUKIKBKGMAPK1AKT3
SCHEMBL13638519 0.86 IKBKB (0.33) IKBKBCHUKIKBKGCDK4CDK1
SCHEMBL13638419 0.86 CDK4 (0.36) IKBKBCHUKIKBKGCDK4CDK1
SCHEMBL13638577 0.86 AKT3 (0.36) IKBKBCHUKIKBKGCDK4CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK IKBKB 2/4885CHUK 3/4885IKBKG 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.